Application of cinnamic acid in preparation of klebsiella pneumoniae capsular inhibitor

By inhibiting the production of capsular polysaccharides in Klebsiella pneumoniae by cinnamic acid and reducing capsular thickness, this invention solves the treatment problem of Klebsiella pneumoniae infection in the prior art, and provides a low-cost and broad-spectrum anti-infective drug lead compound that significantly reduces pathogenicity and improves survival rate.

CN121818593APending Publication Date: 2026-04-10BAODING JIZHONG PHARMA +1
0 Cites 0 Cited by

Patent Information

Application Number
CN202610181154.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-02-09
Publication Date
2026-04-10

AI Technical Summary

Technical Problem

There is currently no application of cinnamic acid in the preparation of Klebsiella pneumoniae capsular inhibitors, and existing strategies such as vaccines, antibodies, and phages that target the capsular are limited by serotype specificity and cannot effectively combat multidrug-resistant Klebsiella pneumoniae infections.

Method used

Using cinnamic acid as a capsular inhibitor, this novel treatment method can reduce capsular thickness and thus inhibit the pathogenicity of Klebsiella pneumoniae by suppressing the production of capsular polysaccharides.

Benefits of technology

Cinnamic acid significantly reduces the pathogenicity of Klebsiella pneumoniae, improves the survival rate of infected giant wax moths, and is non-toxic to mammalian cells within the effective range, providing a lead compound for inexpensive and broad-spectrum anti-infective drugs.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses application of cinnamic acid in preparation of a klebsiella pneumoniae capsular inhibitor and belongs to the technical field of biological medicine, the CAS login number of the cinnamic acid is 140-10-3, the molecular formula of the cinnamic acid is C9H8O2, the molecular weight of the cinnamic acid is 148.16, and the cinnamic acid has an inhibiting effect on klebsiella pneumoniae capsular synthesis. The invention solves the problem that the application of cinnamic acid in preparation of klebsiella pneumoniae capsule inhibitors is not researched and reported at present. Through uronic acid determination, Anthony's capsular staining, a growth curve test, cytotoxicity, a klebsiella pneumonia infection greater wax moth protection test and other analysis, it is proved that cinnamic acid can reduce the pathogenicity of klebsiella pneumonia by inhibiting capsular synthesis, and then the effective anti-infection effect is achieved; a novel treatment means is provided for clinical drug-resistant klebsiella pneumoniae infection, and a lead compound with definite functions is provided for subsequent research.
Need to check novelty before this filing date? Find Prior Art